OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

ATI INC. DL-,01/  US01741R1023  /

München
10/05/2024  08:00:14 Chg. +0.86 Volume Bid21:59:56 Ask21:59:56 Market Capitalization Dividend Y. P/E Ratio
56.30EUR +1.55% 0
Turnover: 0.00		 -Bid Size: - -Ask Size: - 7.01 bill.EUR - -
GlobeNewswire 09/05 TTM Technologies, Inc. Appoints Wajid Ali to Board of Directors
GlobeNewswire 07/05 Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire 27/03 William & Mary Campus Mass Notification Drill Using ATI Systems’ Mass Notification Solution
GlobeNewswire 12/03 Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
GlobeNewswire 13/02 Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
GlobeNewswire 06/02 Seoul Robotics to Pursue Initial Public Offering with Samsung Securities as it Expands OEM Partnersh...
GlobeNewswire 25/01 Confluent Announces Significant Investment in ATI Nitinol Melt Expansion
GlobeNewswire 17/01 IBN Coverage Initiated for Astrotech Corp.
GlobeNewswire 16/01 Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
GlobeNewswire 27/12/2023 Eco Bright Future, Inc. Announces Signing of "Letter-of-Intent" With United Heritage, Sociedad Anoni...
GlobeNewswire 12/12/2023 Astrotech Announces Exciting New Technology Application and Introduces New Subsidiary
GlobeNewswire 05/12/2023 American Trust Insurance Joins World Insurance Associates
GlobeNewswire 27/11/2023 ATI Systems Honored with 2023 ‘ASTORS’ Homeland Security Award
GlobeNewswire 13/11/2023 Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (AT...
GlobeNewswire 06/11/2023 Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
GlobeNewswire 27/10/2023 Strategic Advisory Board Elevates sureti’s Property Claims Resolution Capabilities
GlobeNewswire 25/10/2023 Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT...
GlobeNewswire 23/10/2023 ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...
GlobeNewswire 19/10/2023 Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV a...
GlobeNewswire 03/10/2023 Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic De...
GlobeNewswire 30/09/2023 ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...
GlobeNewswire 19/09/2023 ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...
GlobeNewswire 18/09/2023 Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-21...
GlobeNewswire 30/08/2023 Churchill Franklin Automotive Launches Airbag Alert News Service
GlobeNewswire 17/08/2023 Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its Firs...